Nuzenio

Lutetium Lu

Lutetium Lu news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMT Dr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC - onclive.comonclive.com · Thu, 06 Aug 2026 16:51:58 GMT FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed CareThe American Journal of Managed Care · Mon, 03 Aug 2026 17:37:08 GMT FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI for Prostate Cancer - Oncology News CentralOncology News Central · Mon, 03 Aug 2026 10:27:38 GMT FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 21:11:29 GMT FDA OKs Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 20:58:12 GMT

Timeline

Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis

Thu, 06 Aug 2026 16:51:58 GMTDr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC - onclive.com

Mon, 03 Aug 2026 17:37:08 GMTFDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care

Mon, 03 Aug 2026 10:27:38 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI for Prostate Cancer - Oncology News Central

Fri, 31 Jul 2026 21:11:29 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer - Targeted Oncology

Fri, 31 Jul 2026 20:58:12 GMTFDA OKs Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer - CancerNetwork

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

PSMA4 live mentions Vipivotide Tetraxetan4 live mentions FDA Approves Lutetium4 live mentions Vipivotide Tetraxetan Plus4 live mentions ARPI4 live mentions Pluvicto2 live mentions Dr Morris2 live mentions FDA Approval2 live mentions Earlier2 live mentions Stage Prostate Cancer2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Lutetium Lu.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.